PharmEasy sees 92% cut in valuation at $458 million

API Holdings, the parent company of online pharmacy PharmEasy, has seen a 92% markdown in its valuation — plunging from a peak of $5.6 billion in 2021 to $458 million, according to recent SEC filings.

Global asset management firm Janus Henderson, which made its first investment in PharmEasy during the company’s Series F funding round in 2021, has reduced its valuation of the company. The firm, which initially invested approximately $100 million, has marked down its investment by 91.8%, reflecting a profound loss in investor confidence.